We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of Image-guided Dosimetry for Interstitial Prostate Brachytherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00426959
Recruitment Status : Completed
First Posted : January 25, 2007
Last Update Posted : November 14, 2012
United States Department of Defense
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center

Brief Summary:

This will be a phase I study. This phase I study is not a standard drug dose escalation study, but rather a Clinical System Performance Evaluation Trial of a therapeutic device. However for purposes of this protocol we will refer to this portion of the trial as a phase I study.

The purpose of this study is to demonstrate the feasibility and clinical practicability of the registered ultrasound and fluoroscopy (RUF) in combination with CMS Interplant system® in an initial cohort of 6 patients.

This will involve demonstrating the feasibility of using the system in an actual operating room environment as well as obtaining a preliminary assessment of the accuracy and performance of the source location algorithm by comparing with postoperative CT dosimetry.

The Primary endpoint of this study will be evaluation of the feasibility of using the RUF system and of performing real-time optimization in the operating room environment.

The Secondary endpoints of this study will be:

  1. Acute and late toxicity as assessed by IPSS, SHIM, and EPIC questionnaires at multiple follow-up intervals.
  2. PSA-free survival.

Study Population:

The target population will be patients with a diagnosis of adenocarcinoma of the prostate who are seen in consultation at the Johns Hopkins Hospital.

Approximately 360 patients per year with the diagnosis of prostate cancer are seen in the Department of Radiation Oncology at Johns Hopkins Hospital. Of these patients, approximately 45% have low-risk (T1a-T2a, Gleason 6 or less, PSA 10 ng/ml or less) or intermediate-risk disease and are suitable for brachytherapy based on disease risk. Within this group of patients, approximately 70% are eligible for brachytherapy based on gland size and no prior transurethral resection of prostate (TURP).

Approximately 80% of patients offered brachytherapy at consultation decide to receive their treatment at Johns Hopkins. Overall, we currently perform 2 brachytherapy procedures per week on average, for a yearly total of approximately 90 cases.

For purposes of homogeneity of treatment and patient population, this protocol will only enroll patients currently treated at this institution with brachytherapy alone, and will not enroll patients (intermediate or high risk disease) who will require external beam radiation in addition to brachytherapy.

Condition or disease Intervention/treatment Phase
Locally Confined Adenocarcinoma of the Prostate Device: Image Guided Dynamic Dosimetry Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Feasibility Study of Image-guided, Dynamic Dosimetry for Permanent Interstitial Prostate Brachytherapy
Study Start Date : February 2005
Primary Completion Date : April 2010
Study Completion Date : April 2010

Intervention Details:
    Device: Image Guided Dynamic Dosimetry
    Image Guided Dynamic Dosimetry

Primary Outcome Measures :
  1. Evaluation of the feasibility of using the RUF system. [ Time Frame: 5 years ]
  2. Evaluation of real-time optimization in the operating room environment. [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Acute & late toxicity as assessed by IPSS, SHIM, & EPIC questionnaires. [ Time Frame: 5 years ]
  2. PSA-free survival. [ Time Frame: 5 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed, locally confined adenocarcinoma of the prostate
  • PSA of less than 10 ngmL
  • Combined Gleason score 6 or less, with no individual Gleason score of 4 or 5
  • The patient has decided to undergo brachytherapy at the Johns Hopkins Hospital as treatment choice for his prostate cancer
  • Karnofsky Performance Status greater than 70
  • Prostate volume by TRUS less than 50 cc
  • International Prostate symptom score must be 18 or less
  • Signed study-specific consent form prior to registration

Exclusion Criteria:

  • Clinical or Pathological Lymph node involvement,
  • Evidence of distant metastases
  • Radical surgery for carcinoma of the prostate
  • Chemotherapy or pelvic radiation therapy
  • Previous transurethral resection of the prostate
  • Previous or concurrent cancers other than basal or squamous cell skin cancers unless disease free for at least 5 years.
  • Significant obstructive symptoms
  • Major medical or psychiatric illness which, in the investigator's opinion, Hip prosthesis
  • Anatomic or medical condition (such as prior abdominal perineal resection or anal stricture) which would preclude the use of TRUS Implanted device or apparatus which might obstruct visibility of the implanted sources on fluoroscopy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00426959

United States, Maryland
The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University
Baltimore, Maryland, United States, 21231
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
United States Department of Defense
Principal Investigator: Danny Song, M.D. Johns Hopkins University

Additional Information:
Responsible Party: Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00426959     History of Changes
Other Study ID Numbers: J-04100
First Posted: January 25, 2007    Key Record Dates
Last Update Posted: November 14, 2012
Last Verified: November 2012

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
Adenocarcinoma of the prostate
PSA of less than 10 ng/mL
Combined Gleason score 6 or less
International Prostate Symptom Score (IPSS) must <or= to 18

Additional relevant MeSH terms:
Prostatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases